The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil
Othman Al-Sawaf, MD, of the University Hospital of Cologne, Cologne, Germany, discusses efficacy and safety results from the multicenter, open-label, randomized Phase III CLL14 study (NCT02242942) investigating the efficacy and safety of obinutuzumab and venetoclax versus obinutuzumab and chlorambucil in chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
